News Archive

May 2022
Alentis Therapeutics

Alentis Therapeutics Appoints Dr. Andrea Pellacani as Chief Medical Officer
May 2022
Engimmune Therapeutics

Engimmune Therapeutics Raises CHF 15.5 Million in Seed Financing to Develop Novel T-Cell Receptor Therapeutics
April 2022
AM-Pharma

400 Patients Have Been Enrolled an AM-Pharma’s Pivotal Phase 3 Study of Ilofotase Alfa for the Treatment of Sepsis-Associated Acute Kidney Injury
April 2022
Acrivon Therapeutics

Acrivon Therapeutics Announces the Appointments of Rasmus Holm-Jorgensen as Chief Financial Officer and Other Senior Executives
April 2022
Araris Biotech

Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
April 2022
ImCheck Therapeutics

ImCheck Provides Updated ICT01 and Pembrolizumab Combination Data from the Phase I/IIa EVICTION Trial at AACR Annual Meeting 2022
March 2022
Lava Therapeutics

LAVA Therapeutics Presents Initial LAVA-051 Clinical Data at the ESMO Targeted Anticancer Therapies Congress 2022
February 2022
Hummingbird Bioscience

Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers
February 2022
ImCheck Therapeutics

ImCheck Announces First Patients Dosed in Phase II of EVICTION Trial for ICT01
February 2022
Lava Therapeutics

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-1207 for Metastatic Castration-Resistant Prostate Cancer
February 2022
ImCheck Therapeutics

For the third year in a row, ImCheck has been awarded by the French Tech as one of the top 120 French start-ups/scale-ups and among 7 French biotech developing innovative therapies
January 2022
ImCheck Therapeutics

ImCheck to Present at 40th Annual J.P. Morgan Healthcare Conference
January 2022
Alentis Therapeutics

Alentis Therapeutics Starts First-in-Human Clinical Trial for the Treatment of Liver and Kidney Fibrosis
December 2021
Acrivon Therapeutics

Acrivon Therapeutics Announces its Scientific Advisory Board with Renowned Oncology Thought Leaders
December 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
November 2021
Hummingbird Bioscience

Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board
November 2021
Lava Therapeutics

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
November 2021
ImCheck Therapeutics

ImCheck Provides Promising Updated Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at SITC Meeting 2021
November 2021
Pureos Bioventures

Pureos Bioventures Invests in Acrivon Therapeutics
November 2021
Araris Biotech

Araris is Expanding its Scientific Advisory Board with Dr. Jeff Sharman and Dr. Clive Stanway
November 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting
November 2021
Pureos Bioventures

Pureos Bioventures Welcomes Dr. Lars Nieba to its Team as Venture Partner
November 2021
Alentis Therapeutics

Alentis Therapeutics Announces Appointments of Luca Santarelli to the Board of Directors and Rafaele Tordjman as Chairperson
October 2021
Hummingbird Bioscience

Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
October 2021
ImCheck Therapeutics

ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
October 2021
Lava Therapeutics

LAVA Therapeutics Receives FDA Orphan Drug Designation for LAVA-051 for the Treatment of Chronic Lymphocytic Leukemia
October 2021
Hummingbird Bioscience

Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers
September 2021
Hummingbird Bioscience

Hummingbird Bioscience Opens New Office and Research Facilities
September 2021
Pureos Bioventures

Pureos Bioventures Expands the Team by the Appointment of Venture Partners
September 2021
ImCheck Therapeutics

ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021
September 2021
Araris Biotech

Araris Biotech Shortlisted in Top 5 of World ADC Awards 2021 in Category “Best ADC Platform Technology“
September 2021
Hummingbird Bioscience

Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors
September 2021
ImCheck Therapeutics

ImCheck to Present Early Patient Response Data from the EVICTION Trial at the ESMO Congress 2021
September 2021
Araris Biotech

Araris Biotech Ranks TOP11 at Swiss Startup Award 2021
September 2021
AM-Pharma

AM-Pharma and Kyowa Kirin Sign Exclusive License Agreement for Commercialization of Ilofotase Alfa in Japan
August 2021
Lava Therapeutics

LAVA Therapeutics Provides Business Update and Reports Second Quarter Results
August 2021
Eyevensys

Eyevensys Raises $12M in a Series B Plus Funding Round
July 2021
Alentis Therapeutics

Alentis Therapeutics Raises USD 67 Million in Series B Financing
July 2021
Lava Therapeutics

LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies
July 2021
ImCheck Therapeutics

ImCheck Publishes Seminal Paper in Cell Reports Elucidating How Butyrophilins Activate Vγ9Vδ2 T cell Function Against Tumor Cells
July 2021
AM-Pharma

AM-Pharma Appoints Mark Altmeyer as Chairman of its Supervisory Board
July 2021
AM-Pharma

AM-Pharma Enrolls First Patient in Japan for Ongoing Phase III SA-AKI Pivotal REVIVAL Trial
June 2021
Corlieve Therapeutics

uniQure to Acquire Corlieve Therapeutics and Advance its Gene Therapy Program to Treat Temporal Lobe Epilepsy (TLE)
May 2021
Hummingbird Bioscience

Hummingbird Bioscience Raises US$125 Million in Series C Financing
April 2021
ImCheck Therapeutics

ImCheck Announces Initiation of U.S. Enrollment in Phase I/IIa EVICTION Trial for ICT01
April 2021
Pureos Bioventures

Pureos Bioventures Expands Fund Size to USD 205 Million
More News News Archive